Light pollution, reproductive function and cancer risk

Neuroendocrinology Letters

Volumn 27, Issue 1-2, 2006, Pages 35-52

  Anisimov, Vladimir N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

Author keywords

Anovulation; Carcinogenesis; Circadian rhythm; Life span; Light at night; Melatonin; Shift work

Indexed keywords

MELATONIN;

BREAST CANCER; CANCER; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CIRCADIAN RHYTHM; COLON CANCER; DISEASE ASSOCIATION; HUMAN; LIFESTYLE; LIGHT DARK CYCLE; LIGHT EXPOSURE; NIGHT; NIGHT WORK; NONHUMAN; OCCUPATIONAL EXPOSURE; PINEAL GLAND FUNCTION; PINEALECTOMY; REPRODUCTION; REVIEW; SHIFT WORKER;

EID: 33745651837     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (216)

1. Abarran MT. Lopez-Burillo S., Pablos MI, et al. 2001. Endogenous rhythms of melatonin, total antioxidant status and superoxide dismutase activity in several tissues of chick and their inhibition by light. J Pineal Res 30:227-233.
2. Anderson LE, Morris JE, Sasser LB, Stevens RG. 2000. Effect of constant light on DMBA mammary tumorigenesis in rats. Cancer Lett 148:121-126.
3. Anisimov SV, Popovic N. 2004. Genetic aspects of melatonin biology. Rev Neurosci 15: 209-230.
4. Anisimov SV, Boheler KR, Anisimov VN. 2002. Microarray technology in studying the effect of melatonin on gene expression in the mouse heart. Dokl Biol Sci 383:90-95.
5. Anisimov VN. 1971. Blastomogenesis in persistent-estrous rats. Vopr Onkol 8:67-75.
6. Anisimov VN. 1987. Carcinogenesis and Aging. Vol 2. Boca Raton: CRC Press.
7. Anisimov VN. 2002. The light-dark regimen and cancer development. Neuroendocrinol Lett 23 (Suppl):28-36.
8. Anisimov VN. 2003. The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 46:221-234.
9. Anisimov VN, Morozov VG, Khavinson VKh, Dilman VM. 1973. Correlation of anti-tumor activity of pineal and hypothalamic extracts, melatonin and sygetin in mouse transplantable mammary tumor. Vopr Onkol 10:99-101.
10. Anisimov VN, Zhukova OV, Beniashvili DSh, Bilanishivili VG, Menabde MZ. 1994. Light deprivation, electromagnetic fields and mammary carcinogenesis. Adv Pineal Res 7:229-234.
11. Anisimov VN, Zhukova OV, Labunets IF, Bartsch H, Bartsch C. 1995. The inhibitory effect of light deprivation on N-nitrosomethylurea-induced carcinogenesis and on the growth of transplanted tumors in rodents: possible involvement of the pineal gland and the immune system. Exp Oncol 17(1):47-54.
12. Anisimov VN, Popovich IG, Zabezhinski MA. 1997. Melatonin and colon carcinogenesis: I. Inhibitory effects of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis 18:1549-1553.
13. Anisimov VN, Kvetnoy IM, Chumakova NK, Kvetnaya TV, Molotkov AO, Pogudina NA, et al. 1999. Melatonin and colon carcinogenesis. II. Intestinal melatonin-containing cells and serum melatonin levels in rats with 1,2-dimethylhydrazine-induced colon tumors. Exp Toxicol Pathol 51:47-52.
14. Anisimov VN, Zabezhinski MA, Popovich IG, Musatov SA, Andre V, Godard F, Sichel F. 2000. Inhibitory effect of melatonin on 7,12-dimethylbenz[alanthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett 156:199-205.
15. Anisimov VN, Zavarzina NY, Zabezhinski MA, Popovich IG, Zimina OA, Shtylick AV, et al. 2001. Melatonin increases both life span and tumor incidence in female CBA mice. J Gerontol Biol Sci 56A: B311-B323.
16. Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinski MA, Manton KG, et al. 2003a. The effect of melatonin treatment regimen on mammary adenocarcinoma development in HER-2/neu transgenic mice. Int J Cancer 103:300-305.
17. Anisimov VN, Alimova IN, Baturin DA, Popovich IG, Zabezhinsri MA, Rosenfeld SV, et al.2003b. Dose-dependent effect of melatonin on life span and spontaneous tumor incidence in female SHR mice. Exp Gerontol 38:449-461.
18. Anisimov VN, Baturin DA, Popovich IG, Zabezhinski MA, Mantron KG, Semenchenko AV, et al. 2004. Effect of exposure to light-at-night on life span and spontaneous carcinogenesis in female CBA mice. Int J Cancer 111:475-479.
19. Anisimov VN, Ukraintseva SV, Yashin AI, 2005. Cancer in rodents: does it tell us about cancer in humans? Nat Rev Cancer 5:807-819.
20. Arendt J. 1995 Melatonin and the Mammalian Pineal Gland. London: Chapman & Hall.
21. Arendt J. 2005. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 20: 291-303.
22. Arutjunyan AV, Kerkeshko GO, Anisimov VN, Stepanov MG, Prokopenko VM, Pozdeev NV, et al. 2001. Disturbances of diurnal rhythms of biogenic amines contents in hypothalamic nuclei as an evidence of neurotropic effects of enterotropic carcinogen 1,2-dimethylhydrazyine. Neuroendocrinol Lett 22:229-237.
23. Aschheim P. 1976. Aging in the hypothalamic-hypophyseal-ovarian axis in the rat. In: Everitt AV, Burgess JA, eds. Springfield: Charles C Tomas, pp. 376-392.
24. Aubert C, Janiaud P, Lecalvez J. 1980. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under different conditions of lighting. J Neural Transmiss 47:121-130.
25. Barbacka-Surowiak G, Surowiak J, Stoklosowa S. 2003. The involvement of the suprahiasmatic nuclei in the regulation of estrous cycles in rodents. Reproduct Biol 3:99-129.
26. Barnes JW, Tischkau SA, Barnes JA, Mitchell JW, Burgoon PW, Hickok JR, Gillette MU. 2003. Requirement of mammalian Timeless for circadian rhythmicity. Science 302:439-442.
27. Bartsch C, Bartsch H, Gupta D. 1990. Pineal melatonin synthesis and secretion during induction and growth of mammary cancer in female rats. In: Neuroendocrinology: New Froniters. Gupta D, Wollmann HA, Ranke MB, eds. London and Tubingen: Brain Research Promotion, pp. 326-332.
28. Bartsch C, Bartsch H. 1999. Effects of melatonin and constant light on the development of spontaneous endometrial carcinomas in aging BDII/Han rats appear to be exerted by modulatinf maturation of the reproductive system. Z Gerontol Geriatrie 32 (Suppl 2):II/5.
29. Bartsch H, Bartsch C, Mecke D. 2001. The modulation of melatonin in tumor-bearing animals: underlying mechanisms and possible significance for prognosis. In: Bartsch C, Bartsch H, Blask DE, Cardinali DR Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp.197-209.
30. Baturin DA, Alimova IN, Anisimov VN, Popovich IG, Zabezhinski MA, Provinciali M, Mancini R, Franceschi C. 2001. Effect of light regime and melatonin on the development of spontaneous mammary tumors in HER-2/neu transgenic mice is related to a down-regulation of HER-2/neu gene expression. Neuroendocr Lett 22:439-445.
31. Baturin DA, Alimova IN, Popovich IG, Zabezhinskii MA, Semenchenko AV, Yashin AI, et al. 2004. Effect of light deprivation on homeostasis, life span and development of spontaneous tumors in HER-2/ neu transgenic mice. Vopr Onkol 50:332-338.
32. Baydas G, Ercel E, Canatan H, Donder E, Akyol A. 2001. Effect of melatonin on oxidative status of rat brain, liver and kidney tissues under constant light exposure. Cell Biochem Funct 19:37-41.
33. Bell JA, Sneddon A, Hamilton T. 1968. Influence of light and 9,10-dimethylbenz(a) anthracene on rat ovarian steroidogenesis: neutral steroids. Biochem J 110:29p-30p.
34. Bell-Pedersen D, Cassone VM, Earnest DJ, Golden SS, Hardin PE, Thomas TL, Zoran MJ. 2005. Circadian rhythms from multiple oscillators: lessons from diverse organisms. Nat Rev Genet Advance online publ. 10 June 2005; doi:10.1038/nrd1633.
35. Beniashvili DS, Benjamin S, Baturin DA, Anisimov VN. 2001. Effect of light/dark regimen on N-nitrosoethylurea-induced transplacental carcinogenesis in rats. Cancer Lett 163:51-57.
36. Benot S, Molinero P, Soutto M, Goberna R, Guirrero JM. 1998. Circadian variation in the rat serum total antioxidant status: correlation with melatonin levels. J Pineal Res 25:1-4.
37. Berson DM, Dunn FA, Takao M. 2002. Phototrsansduction by retinal ganglion cells that set the circadian clock. Science 295:1070-1073.
38. Blask DE. 1984.The pineal: an oncostatic gland. In: Reiter RJ, ed. The Pineal Gland. New York: Raven Press, pp. 253-284.
39. Blask DE. 2001. An overview on the neuroendocrine regulation of experimental tumor growth by melatonin and its analogues and the therapeutic use of melatonin in oncology. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp. 309-342.
40. Blask DE, Hill SM. 1986. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J Neural Transm (Suppl)21:433-449.
41. Blask DE, Hill SM, Orstead KM, Massa JS. 1986. Inhibitory effects of the pineal hormone melatonin and underfeeding during the promotion phase of 7,12-dimethylbenz[a]-anthracene-(DMBA)-induced mammary tumorigenesis. J Neural Transm 67:125-138.
42. Blask DE, Hill SM, Pelletier DB. 1988. Oncostatic sygnaling by the pineal gland and melatonin in the control of breast cancer. In: Gupta D, Attanasio A, Reiter RJ, eds. The Pineal Gland and Cancer. London: Brain Research Promotion, pp. 221-232.
43. Blask DE, Pelletier DB, Hill SM, Lemus-Wilson A, Grosso DS, Wilson ST, et al. 1991. Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117:526-532.
44. Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC. 2003. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat 79:313-320.
45. Brainard GC, Hanifin JR. 2005. Photons, clocks, and consciousness. J Biol Rhythms 20: 314-325.
46. Brainard GC, Kaver R, Kheifets LI. 1999. The relationship between electromagnetic field and light exposure to melatonin and breast cancer risk: a review of the relevant literature. J Pineal Res 26:65-100.
47. Brainard GC, Hanifin JP, Greeson J, Byrne N, Glickman G, Gerner E, et al. 2001. Action spectrum of melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 21: 6405-6412.
48. Canaple L, Kakizawa T, Laudet V. 2003. The days and nights of cancer cells. Cancer Res 63:7545-7552.
49. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. 2005. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26:1241-1246.
50. Chernova IV. 2005. Light regimens and estrous cycle in rats. Med Acad J 3, Suppl. 7:45-46.
51. Chung FF, Yao CC, Wan GH. 2005. The associations between menstrual function and life style/working conditions among nurses in Taiwan. J Occup Health 47:149-156.
52. Cos S, Sanchez-Barcel EJ. 1995. Melatonin inhibition of MCF-7 human breast cancer cell growth: influence on cell proliferation rate. Cancer Lett 93:207-212.
53. Cos S, Sanchez-Barcel EJ. 2000. Melatonin and mammary pathological growth. Front Neuroendocrinol 21:133-170.
54. Cos S, Sanchez-Barcelo EJ. 2001. In vitro effects of melatonin on tumor cells. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp. 221-239.
55. Cos S, Mediavilla D, Martinez-Campa C, Gonzalez A, Laonso-Gonzalez C, Sanchez-Barcelo EJ. 2006. Exposure to ligh-at-night increases the growth of DMBA-induced mammary adenocarcinomas in rats. Cancer Lett 235:266-271.
56. Cos S, Gonzalez A, Guezmes A, Mediavilla MD, Martinez-Campa C, Alonso-Gonzalez C, et al. 2006. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasibg the local biosyhthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118:274-278.
57. Dauchy RT, Blask DE, Sauer LA, Brainard JC, Krause JA. 1999. Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism. Cancer Lett 144:131-136.
58. Dauchy RT, Sauer LA, Blask DE, Vaughan GM. 1997. Light contamination during the dark phase in 'photoperiodically controlled' animal rooms: effect on tumor growth and metabolism in rats. Lab Anim Sci 47:511-518.
59. Davis S, Kaune WT, Mirick DK, Chen C, Stevens RG. 2001. Residental magnetic fields, light-at-night, and nocturnal urinary 6-sulfatoxymelatonin concentration in women. Am J Epidemiol 154:591-600.
60. Davis S, Mirick DK, Stevens RG. 2001a. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557-1562.
61. Depres-Brummer P, Levi F, Metzger G, Touitou Y. 1995. Light-induced suppression of the rat circadian system. Am J Physiol 268: R1111-R1116.
62. Dilman VM. 1994. Development, Aging and Disease. A New Rationale for an Intervention Strategy. Chur: Harwood Acad Publ.
63. Dilman VM, Anisimov VN. 1979. Hypothalamic mechanisms of ageing and of specific age pathology - I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Exp Gerontol 14:161-174.
64. Di Lorenzo L, De Pergola G, Zocchetti C, L'Abbate N, Basso A, Pannacciulli N, et al. 2003. Effect of shift work on body mass index: results of a study performed in 319 glucose-tolerant men working in a Southern Italian industry. Int J Obes Relat Metab Disord 27:1353-1358.
65. Eck-Enriquez K, Kiefer TL, Spriggs LL, Hill SM. 2000. Pathways through which a regimen of melatonin and retinoic acid induced apoptosis in MCF-7 human breast cancer cells. Breast Cancer Rse Treat 61:229-239.
66. Feychting M, Oosterlund B, Ahlbom A. 1998. Reduced cancer incidence among the blind. Epidemiology 9:490-494.
67. Filipski E, King VM, Li XM, Granda TG, Mormont MC, Liu XH, et al. 2002. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 94:690-697.
68. Filipski E, King VM, Li XM, Granda TG, Mormont MC, Claustrat B, et al. 2003. Disruption of circadian coordination accelerates malignant growth in mice. Pathologie Biologie 51:216-219.
69. Filipski E, Dellaunay F, King VM, Wu MW, Claustrat B, Grechez-Cassiau A, et al. 2004. Effects of chronic jet lag on tumor progression in mice. Cancer Res 64:7879-7885.
70. Filipski E, Innominato PF, Wu MW, Li XM, lacobelli S, Xiam U, et al. 2005. Effects of light and food schedules on liver and tumor molecular clocks in mice. J Natl Cancer Inst. 97:507-517.
71. Fu L, Lee CC. 2003. The circadian clock: pacemaker and tumour suppressor. Nature Rev Cancer 3:350-361.
72. Fu L, Pelicano H, Liu J, Huang P, Lee CC. 2002. The circadian gene Period2 plays an importnat role in tumor suppression and DNA damage response in vivo. Cell 111: 41-50.
73. Gauger MA, Sancar A. 2005. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res 65:6828-6834.
74. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, Takahashi JS, Weitz CJ. 1998. Role of the CLOCK protein in the mammalian circadian mechanism. Science 280:1564-1569.
75. Goto M, Ebihara S. 1990. The influence of different light intensities on pineal melatonin content in the retina; degenerate C3H mouse and the normal CBA mouse. Neucrosci Lett 108:267-272.
76. Graham C, Cook MR. 2001. Examination of the melatonin hypothesis in women exposed at night to EMF or bright light. Environ Health Perspect 109:501-507.
77. Ha M, Park J. 2005. Shiftwork and metabolic risk factors of cardiovascular disease. J Occup Health 47:89-95.
78. Hahn RA. 1991. Profound bilateral blindness and the incidence of breast cancer. Epidemiology 2:108-210.
79. Hamilton T. 1969. Influence of environmental light and melatonin upon mammary tumour induction. Br J Surg 56:764-766.
80. Hamilton T, Sneddon A. 1968. Environmental light and DMBA- induced rat mammary tumours. Br J Surg 55:71-76.
81. Hansen J. 2001. Increased breast cancer risk among women who work predominantly at night. Ann Epidemiology 12:74-77.
82. Hansen J. 2002. Re: Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 97:533-534.
83. Harlow SD, Ephross SA. 1995. Epidemiology of menstruation and its relevance to women's health. Epidemiol Rev 17: 265-286.
84. Harman D. 1994. Free-radical theory of aging: increasing the functional life span. Ann NY Acad Sci 717:257-266.
85. Haus E, Lakatua D, Hallberg F. 1967. The internal timing of several circadian rhythms in the blinded mouse. Exp Med Surg 25:7-45.
86. Haus E, Dumitriu L, Nicolau GY, Bologa S, Sackett-Lundeen L. 2001. Circadian rhythms of basic fibroblast growth factor (bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), cortisol, and melatonin in women with breast cancer. Chronobiol Int 18:709-727.
87. Hill SM, Kiefer T, Teplitzky S, Spriggs LL, Ram PT. 2001. Modulation of the estrogen response pathway in human breast cancer cells by melatonin. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp. 343-358.
88. Hoffmann JC. 1968. Effect of photoperios on estrous cycle length in the rat. Endocrinology 83:1355-1357.
89. Honma S., Kawamoto T, Takagi Y, Fujimoto K, Sato F, Noshiro M, Kato Y, Honma K. 2002. Dec1 and Dec2 are regulators of the mammalian molecular clock. Nature 419:841-844.
90. Hrushesky WJM. 2001. Melatonin cancer therapy. Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp.476-508.
91. Ilyukha VA, Vinogradova IA, Fedorova AS, Velb AN. 2005. Effect of light regimens, pineal hormones and age on antioxidant system of rats. Med Acad J 3, Suppl 7:29-30.
92. Inoue I, Shinoda Y, Ikeda M, Hayashi K, Kanazawa K, Nomura M, et al. 2005. CLOCK/BMAL1 is involved in lipid metabolism via transactivation of the peroxisome proliferator-activated receptor (PPAR) response element. J Atherosclerosis Thromb 12:169-174.
93. Ird EA. 1966. Follicular Cysts of the Ovary and Dyshormonal Tumors. Leningrad: Meditsina.
94. Isobe Y, Nishino H. 2004. Signal transmission from the suprachiasmatic nucleus to the pineal gland via the paraventricular nucleus: analysed from arg-vasopressin peptide, rPer2 mRNA and AVP mRNA changes and pineal AA-NAT mRNA after the melatonin injection during light and dark periods. Brain Res 1013:204-211.
95. Ivanisevic-Milovanocic OK, Demajo M, Karakasevic A, Pantic C. 1995. The effect of constant light on the concentration of catecholamines of the hypothalamus and asdrenal glands, circulatory adrenocorticotropin hormone and progesterone. J Endocr Invest 18:378-383.
96. Johle W. 1964. Trends in photophysiologic concept. Ann NY Acad Sci 11:88-104.
97. Jull JW. 1966. The effect of infection, hormonal environment, and genetic constitution on mammary tumor induction in rats by 7,12-dimethylbenz(a)anthracene. Cancer Res 26:2368-2373.
98. Karolczak M., Burbach GJ, Sties G, Korf HW, Stehle JH, 2004. Clock gene mRNA and protein rhythms in the pineal gland of mice. Eur J Neurosci 19:3382-3388.
99. Kerenyi N. 2002. Re: Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 97:531-532.
100. Khaetski IK. 1964. Carcinogenic effect of DMBA at neuroendocrine disturbances. In: Tumor and Organism. Abstracts of the Symposium. North-Western Book Publisher, pp. 72-74.
101. Khaetski IK. 1965. Effect of hypothalamo-pituitary lesions induced by constant illumination on development of induced mammary tumors in rats. Vopr Exp Oncol (Kiev) 1:87-93.
102. Kilic E, Kilic U, Reiter RJ, Bassetti CI, Hermann DM. 2004. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 37:247-251,
103. King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, Steeves TD, et a]. 1997. Positional cloning of the mouse circadian clock gene. Cell 89:641-653.
104. Kliukiene J, Tynes T, Anderson A. 2001. Risk of breast cancer among Norvegian women with visual impairment. Br J Cancer 84:397-399.
105. Klochkov DV, Beliaev DK. 1977. Effect of continuous illumination on the reproductive function in rats. Aftereffects. Ontogenez 8:487-496.
106. Knutsson A. 2003. Health disorders of shift workers. Occupat Med 53:103-108.
107. Knutsson A, Boggild H. 2000. Shiftwork, risk factors and cardiovascular disease: review of disease mechanisms. Rev Environ Health 15:359-372.
108. Kojo K, Pukkala E, Auvinen A. 2005. Breast cancer risk among Finnish cabon attendants: a nested case-control study. Occup Environ Med 62:488-493.
109. Korf HW, Von Gall C, Stehle J. 2003. The circadian system and melatoni: lessons from rats and mice. Chronobiol Int 20:697-710.
110. Kothari L. 1987. Influence of chronic melatonin on 9,1 0-dimethyl-1,2-benzanthrazene-induced mammary tumors in female Holtzman rats exposed to continuous light. Oncology 44:64-66.
111. Kothari L. 1988. Effect of melatonin on the mammary gland morphology, DNA synthesis, hormone profiles and incidence of mammary cancer in rats. In: Gupta D, Attanasio A, Reiter RJ, eds. The Pineal Gland and Cancer. London: Brain Research Promotion, pp.210-219.
112. Kothari L, Shah PN, Mhatre MC. 1982. Effect of continuous light on the incidence of 9,10-dimethyl-1,2-benzanthracene induced mammary tumors in female Holtzman rats Cancer Lett 16:313-317.
113. Kothari A, Borges A, Kothari L. 1995. Chemoprevention by melatonin and combined melatonin-tamoxifen therapy of second generation nitroso-methylurea-induced mammary tumour in rats. Eur J Cancer Prev 4:497-500.
114. Kothari A, Borges A, Ingle A, Kothari L. 1997. Combination of melatonin and tamoxifen as a chemoprophylaxis against N-ni-troso-N-methylurea-induced rat mammary tumors. Cancer Lett 111:59-66.
115. Koyanagi S, Kuramoto Y, Nagasawa H, Aramaki H, Ohdo S, Soeda S, Shimeno H. 2003. A molecular mechanism regulating circadian expression of vascular endothelial gorwth factos in tumor cells. Cancer Res 63:7277-7283.
116. Kubatka P, Kalicka K, Chamilova M, Ahlersova E, Ahlers I, Bojkova B, et al. 2002. Nimesulide and melatonin in mammary carcinogenesis prevention in female Sprague-Dawley rats. Neoplasma 49:255-259.
117. Kumar CA, Das UN. 2000. Effect of melatonin on two stage skin carcinogenesis in Swiss mcie. Med Sci Monit 6:471-475.
118. Kuralasov AK. 1979. Effect of dark adaptation on carcinogenesis and efficacy of treatment DMBA-induced mammary tumor. Proc Acad Sci Kazakh SSR, Ser Biol 4:79-82.
119. Kuralasov AK. 1990. Experimental Bases for Use of Artificial Photoregimen for Breast Cancer Treatment in Kazakhstan. Diss Doctor Med Sci. Moscow: All-Union Cancer Center.
120. L'Hermite-Baleriaux M., de Launoit Y. 1992. Is melatonin really an in vitro inhibtor of human breast cancer cell proliferation in vitro. Cell Dev Biol 28A:583-584.
121. Lazarev NI, Ird IO, Smirnova IO. 1976. Experimental Models of Endocrine Gynecological Diseases. Moscow: Meditsina.
122. Lee CC. 2005. The circadian clock and tumors suppression by mammalian Period genes. Methods in Enzymology 393:852-861.
123. Lemus-Wilson A, Kelly PA, Blask DE. 1995. Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br J Cancer 72:1435-1440.
124. Lenoir V, de Jonage-Canonico MBY, Perrin MH, Martin A, Scholler R, Kerdelhue B. 2005. Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[alanth racene in the female Sprague-Dawley rat. Breast Cancer Res 7: R470-R476.
125. Leon-Blanco M, Guerriero JM, Reiter RJ, Calvo JR, Pozo D. 2003. Melatonin inhibits telomerase activity in the MCF-7 tumor cell line both in vivo and in vitro. J Pineal Res 35:204-211.
126. Leon-Blanco M, Guerriero JM, Reiter RJ, Pozo D. 2004. RNA expression of human telomerase subunits TR and TERT is differentially affected by melatonin receptor agonists in the MCF-7 tumor cell line. Cancer Lett 216:73-80.
127. Li JC, Xu F. 1997. Influence of light-dark shifting on immune system, tumor growth and life span of rats, mice and fruit flies as well as on the counteraction of melatonin. Biol Signals 6:77-89.
128. Lin MC, Kripke DF, Parry BL, Berga SL. 1990. Night light alters menstrual cycles. Psychiatry Res 33:135-138.
129. Lissoni P. 2001. Efficacy of melatonin in the immunotherapy of cancer using interleukin-2. In: Bartsch C, Bartsch H, Blask DE, Cardinali DIP, Hrushesky WJM, Mecke D, eds.The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp. 463-475.
130. Lissoni P, Barni S, Meregalli S, Fossati V, Cazzanga M, Espositi D, et al. 1995. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 71:854-856.
131. Liu F, Ng TB, Fung MC. 2001. Pineal indoles stimulate the gene expression of immunomodulating cytokines. J Neural Transm 108:397-405.
132. Maestroni GJM. 2001. Melatonin and the immune system: therapeutic potential in cancer, viral diseases, and immunodeficiency states. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp. 384-394.
133. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okahamura H. 2003. Control mechanism of the circadian clock for timing of cell division in vio. Science 302:255-259.
134. Mediavilla MD, Guezmez A, Ramos S, Kothari L, Garijo F, Sanchez-Barcelo EJ. 1997. Effect of melatonin on mammary gland lesions in transgenic mice overexpressing N-ras proto-oncogene. J Pineals Res 22:86-94.
135. Megdal SP, Kroenke CH, Laden F, Pukkala E, Schernhammer ES. 2005. Night work and breast cancer risk: a systemic review and meta-analysis. Eur J Cancer 41:2023-2032.
136. Melancon K, Cheng Q, Kiefer TL, Dai J, Dong C, Yan L, Collins A, Thiyagarajah A, Long S, Hill SM. 2005. Regression of NMU-induced mammary tumors with the combination of melatonin and 9-cisretinoic acid. Cancer Lett 227:39-48.
137. Mhatre MC, Shah PN, Juneja HS. 1984. Effect of various photoperiods on mammary morphology, DNA synthesis, and hormone profile in female rats. J Natl Cancer Inst 72: 1411-1416.
138. Miller BH, Olson SL, Turek FW, Levine JE, Horton TH, Takahashi JS. 2004. Circadian Clock mutation disrupt estrous cyclicity and mainenance of pregnacy. Curr Biol 14:1367-1373.
139. Mockova K, Mnichova M, Kubatka P, Bojkova B, Ahlers I, Ahlersova E. 2000. Mammary carcinogenesis induced in Wistar:Han rats by the combination of ionizing radiation and dimethylbenzanthracene: prevention with melatonin. Neoplasma 47:227-229.
140. Molis T, Walters MR, Hill SM. 1993. Melatonin modulation of estrogen receptor expression in MCF-7 human breast cells. Int J Oncol 3:687-694.
141. Monk TH. 2000. Shift work. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine, 2nd ed. Philadelphia: WB. Saunders Company, pp. 471-476.
142. Mormont MC, Levi F. 1997. Circadian-system alterations during cancer processes: a review. Int J Cancer 70:241-247.
143. Mormont MC, Waterhouse J, Bleuzen P, Giachetti S, Jami A, Bogdan A, et al. 2000. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patinets with metastatic colorectal cancer and good performance status. Clin Cancer Res 6:3038-3045.
144. Munoz M, Peirson SN, Hankins MW, Foster RG. 2005. Long-term constant light constitutive elevated expression of mPER2 protein in the murine SCN: a molecular basis for Aschofff's rule? J Biol Rhythms 20:3-14.
145. Musatov SA, Anisimov VN, Andre V, Vigreux C, Godard T, Gauduchon P, et al. 1998. Modulatory effects of melatonin on genotoxic response of reference mutagens in the Ames test and the comet assay. Mutat Res 417:75-84.
146. Musatov SV, Anisimov VN, Andre V, Vigreuz C, Godard T, Sichel F. 1999. Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay). Cancer Lett 138:37-44.
147. Napalkov NP. 2004. Cancer and demographic transition. Vopr Onkol 50:127-144.
148. Oster H, Baeriswyl S, van der Horst GTJ, Albrecht U. 2003. Loss of circadian rhythmicity in aging mPer1-/- mCry2-/- mutant mice. Genes Dev 17:1366-1379.
149. Panchenko AV. 2005. Colon carcinogenesis in rats maintained at various light regimens. Med Acad J 3, Suppl 7:32-33.
150. Panda S, Nayak SK, Campo B, Walzer JR, Hogenesch JB, Jegla T. 2005. Illumination of the melanopsin signaling pathway. Science 307:600-604.
151. Parkin DM, Bray FL, Deseva SS. 2001. Cancer burden in the year 2000. The global picture. Eur J Cancer 37:S4-S66.
152. Pauley SM. 2004. Ligthing for the human circadian clock: recent research indicates that lighting has become a public health issue. Medical Hypotheses 63:588-596
153. Praast G, Bartsch C, Bartsch H, Mecke D, Lippert TH. 1995. Hepatic hydroxylation of melatonin in the rat is induced by phenoobarbital and 7,12-dimethylbenz[a]anthracene - implications for cancer etiology. Experientia 51:349-355.
154. Prata Lima MF, Baracat EC, Simones MJ. 2004. Effects of melatonin on the ovarian response to pinealectomy or continuous ligh in gfemale rats: similarity with polycystic ovary syndrome. Brazil J Med Biol Res 37:987-995.
155. Pukkala E, Auvinen H., Wahlberg G. 1995. Incidence of cancer among Finnish arline cabin attendants, 1967-92. Br Med J 311:649-652.
156. Pukkala E, Verkasalo PK, Ojamo M, Rudanko SL. 1999. Visual impairment and cancer: a population-based cohort study in Finfland. Cancer Causes Control 10:13-20.
157. Pukkala E, Aspholm R, Auvinen A, Eliasch H, Gundestrup M, Haldorsen T, et al. 2002. Incidence of cancer among Nordic airline pilots over five decades: occupational cohort study. BMJ 325:567-571.
158. Rajaratnam SMW, Arendt J. 2001. Health in a 24-h society. Lancet 358:999-1005.
159. Rafnsson V, Tulinius H, Jonasson J, Hrafnkelsson J. 2001. Risk of breast cancer in female flight attendants: a population-based study (Iseland).Cancer Cause Control 12:95-101.
160. Rao GN, Ney E, Herbert RA. 2000. Effect of melatonin and linolenic acid on mammary cancer in transgenic mice with c-neu breast cancer oncogene. Breast Cancer Res Treatment 64:287-296.
161. Ralph MR, Menaker MA. 1988. A mutation of the circadian system in golden hamsters. Science 241:1225-1227.
162. Reddy AK, Wong GKY, O'Neill J, Maywood ES, Hastings MH. 2005. Circadioan clocks: neural and peripheral pacemakers that impact upun the cell division cycle. Mutat Res S74:76-91.
163. Reiter RJ. 1980. The pineal and its hormones in the control of reproduction in mammals. Endocrin Rev 1:109-131.
164. Reiter RJ. 2001. Reactive oxygen species, DNA damage, and carcinogenesis: intervention with melatonin. In: Bartsch C, Bartsch H, Blask DE, Cardinali DP, Hrushesky WJM, Mecke D, eds. The Pineal Gland and Cancer. Neuroimmunoendocrine Mechanisms in Malignancy. Berlin: Springer, pp. 442-455.
165. Reiter RJ. 2002. Potential biological consequences of excessive light exposure: melatonin suppression, DNA damage, cancer and neurodegenerativr diseases. Neuroendocrinol Lett 23, Suppl 2: 9-13.
166. Reiter R. 2004. Mechanisms of cancer inhibition by melatonin. J Pineal Res 37:213-214.
167. Reppert SM, Weaver DR. 2002. Coordination of circadian timing in mammals. Nature 418:935-941.
168. Reynolds P, Cone J, Layefsky M, Goldberg DE, Hurley S. 2002. Cancer incidence in California flight attendants (United States). Cancer Causes Control 13:317-324.
169. Roenneberg T, Merrow M. 2003. The network of time: understanding the molecular circadian system. Curr Biol 113:R198-R207.
170. Rossmanith WG. 1996. Gonadotropin secretion during aging in women: review article. Exp Gerontol 30:369-381.
171. Sanchez-Barcelo EJ, Cos S, Mediavilla MD. 1988. Influence of pineal function on the initiation and growth of hormone-dependent breast tumors. Possible mechanisms. In: Gupta D, Attanasio A, Reiter RJ, eds. The Pineal Gland and Cancer. London: Brain Research Promotion, pp. 221-232.
172. Schernhammer ES, Hankinson SE. 2005. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 97:1084-1087.
173. Schernhammer ES, Schulmeister K. 2004. Melatonin and cancer risk: does light at night compromise physiologic cancer protection by lowering serum melatonin levels? Br J Cancer 90:941-943.
174. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. 2001. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 93:1563-1568.
175. Schernhammer ES, Laden F, Spezer FE, Willett WC, Hunter DJ, Kawachi I, et al. 2003. Night-shift work and risk of colorectal cancer in the Nurses' Health Study. J Natl Cancer Inst 95:825-828.
176. Schernhammer ES, Rosner B, Willett WC, Laden F, Coldiz GA, Hankinson SE. 2004. Epidemiology of urinary melatonin in women and its relation to other hormones and night work. Cancer Epidemiol Biomarkers Prev 13:936-943.
177. Seshardi R, Subramnanian A, Kothari L. 1992. Effect of neonatal pineal ablation on estradiol receptors in mammary glands of rats housed under varying photoperiods. Indian J Exp Biol 30:162-164.
178. Shah PN, Mhatre MC, Kothari L. 1984. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res 44:3403-3407.
179. Shephton S, Spiegel D. 2003. Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 17:321-328.
180. Sibarov DA, Kovalenko RI, Nozdrachev AD, Anisimov VN. 2000. Daytime pineal gland activation in rats with colon tumors induced by 1,2-dimethylhydrazine. Neuroendocrinol Lett 21:307-312.
181. Simmonneaux V, Poirel VJ, Garidou ML, Nguen D, Diaz-Rodriguez E, Pevet P. 2004. Daily rhythm and regulation of clock gene expression in the rat pineal gland. Mol Brain Res 120:164-172.
182. Smirnova IO. 1966. Experimental Bases of Treatment of Mastopathy with Iodine Microcloses. PhD Thesis. Moscow: All-Union Cancer Center.
183. Smyth BJ, Sneddon A, Hamilton T. 1968. Influence of light and 9,10-dimethylbenz(a)anthracene on rat ovarian steroidogenesis: phenolic steroids. Biochem J 110:28p-29p.
184. Steenland K, Fine L. 1996. Shift work, shift change, and risk of death from heart disease at work. Am J Industr Med 29:278,281.
185. Stevens RG. 2005. Circadian disruption and breast cancer. From melatonin to clock genes. Epidemiology 16:254-258.
186. Stevens RG, Rea MS. 2001. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 12:279-287.
187. Subramanian A, Kothari L. 1991. Melatonin, a suppressor of spontaneous murine mammary tumors. J Pineal Res 10:136-140.
188. Subramanian A, Kothari L. 1991a. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzathracene (DMBA)-induced rat mammary gland carcinogenesis. Anticancer Drugs 2:297-303.
189. Takumi T, Taguchi K, Miyake S, Sakakida Y, Takashima N, Matsubara C, et al. 1998. A light-independent oscillatory gene mPer3 in mouse SCN and OVLT. EMBO J 17:4753-4759.
190. Tamarkin L, Cohen D, Roselle C, Reichert M. 1981. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz[a]anthracene-induced mammary tumors in the rat. Cancer Res 41:4432-4436.
191. Taylor PJ, Pocock SJ. 1972. Mortality of shift and day workers 1956-68. Brit J Industr Med 29:201-207.
192. Tel H, Okamura H, Shigeyoshi Y, Fukuhara C, Ozawa R, Hirose M, Sakaki Y. 1997. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature 389:512-516.
193. Tenkane L, Sjoblom T, Kalino T, Alikoski T, Harma M. 1997. Shift work, occupation and coronary heart disease over a 6-years of follow up in the Helsinki Heart Study. Scand J Work Environ Health 23:257-265.
194. Toh KL, Jones CR, He Y, Eide EJ, Hinz WA, Virshup DM, Ptacek LJ, Fu YH. 2001. An hPer2 phoshorylation site mutation in familiall advanced sleep ohase syndrome. Science 291:1040-1043.
195. Travlos GS, Wilson RE, Murrell JA, Chignell CF, Boorman GA. 2001.The effect of short intermittent light exposure on the melatonin circadian rhythm and NMU-induced breast cancer in female F344/N rats. Toxicol Pathol 29:126-136.
196. Thresher RJ, Vitaterna MH, Miyamoto Y, Kazantsev A, Hsu DS, Petit C, et al. 1998. Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses. Science 282:1490-1494.
197. Turek FW, Joshu C, Kohsaka A, Lin E., Ivanova G., McDearmon E, et al. 2005. Obesity and metabolic syndrome in circadian Clock mutant mice. Science 308:1043-1045.
198. Tynes T, Hannevik M, Andersen A, Vistnes Aim Haldorsen T. 1996. Incidence of breast cancer in Norwegian female radio and telegraph operators. Cancer Causes Control 7:197-204.
199. Van den Heilignerberg S, Depres-Brummer P, Barbason H, Claustrat B, Reynes M, Levi F. 1999. The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sci 64:2523-2534.
200. Van der Horst GT, Muijtjens M, Kobayashi K, Takano R, Kanno S, Takao M, de Wit J, Verkerk A, Eker AP van Leenen D, Buijs R, Bootsma D, Hoeijmakers JH, Yasui A. 1999. Mammalian Cry1 and Cry2 are essential for maintenance of circadian rhythms. Nature 398:627-630.
201. Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko SL. 1999. Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br J Cancer 80:1459-1460.
202. Vesnishkin GM, Plotnikova NA, Semenchenko AV, Anisimov VN. 2005. Melatonin inhibits carcinogenesis induced by benzo(a)pyrene in mice. J Exp Clin Cancer Res, submitted.
203. Vesnishkin GM, Plotnikova NA, Semenchenko AV, Anisimov VN. 2006. Melatonin inhibits lung carcinogenesis induced by urethane in mice. Vopr Onkol 52:164-168.
204. Vijayalaxmi, Reiter RJ, Meltz ML. 1998. Melatonin reduces gamma radiation-induced primary DNA damage in human blood lymphocytes. Mutat Res 397:203-208.
205. Vijayalaxmi, Thomas CR, Reiter RJ, Herman TS. 2002. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575-2601.
206. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, Dove WF, Pinto LH, Turek FW, Takahashi JS. 1994. Mutagenesis and mapping of a mouse gene, Clock, essential for circadian behavior. Science 264:719-725.
207. Vinogradova IA, Shevchenko AI. 2005. Effect of light regimen on indices of biological age and age-related pathology. Med Acad J 3; Suppl 7:18-20.
208. Van Gall C, Weaver DR, Moek J, Jilg A, Stehle JH, Korf HW. 2005. Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. Ann NY Acad Sci 1040:508-511.
209. Weisburger JH, Rivenson A, Choi CI, Reinhardt J, Pittman B, Zang E. 2003. Inhibition of lung, mammary gland and colon tumors by melatonin. Proc Am Assoc Cancer Res, Abstract #5694; 44(2nd ed):1133-1134.
210. Welsch CW. 1985. Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Benton Huggins. Cancer Res 45: 3415-3443.
211. Wise PM, Gerhold LM, Cashion AB. 2005. Neuroendocrine modulation of menopause: evolution of our thinking. In: Hormones, Age and Cancer. Berstein LM (Ed). St.Petersburg, Nauka, pp. 94-111.
212. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, et al. 2000. Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. Endocrinology 141:487-497.
213. Young MW, Kay SA. 2001. Time zones: a comparative genetics of circadian clocks. Nat Rev Genet 2:702-715.
214. Zeitzer JM, Dijk DJ, Kronauer R, Brown E, Czeisler C. 2000. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol 526:695-702.
215. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. 2005. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 14:268-270.
216. Zhukova OV, Anisimov VN. 1994. Effect of light deprivation on carcinogenesis induced by N-nitrosomethylurea in female rats. Vopr. Onkol 40(1-3):71-75.